• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2021
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2021
    • Multiple Sclerosis Nurses at the Limits 2021
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor Mark Lemmon

Mark A. Lemmon, Ph.D. is the David A. Sackler Professor of Pharmacology, and Co-Director of the Cancer Biology Institute at Yale University.  He has just moved to Yale after 19 years at the University of Pennsylvania Perelman School of Medicine, where he was the George W. Raiziss Professor and Chair of Biochemistry and Biophysics and an Investigator in the Abramson Family Cancer Research Institute.  Dr. Lemmon received his B.A. (Hons, First Class) in Biochemistry from the University of Oxford (Hertford College), England in 1988, and then moved to Yale for his Ph.D., which he did with Donald M. Engelman in the Department of Molecular Biophysics and Biochemistry as an HHMI Predoctoral Fellow.  In 1993, he moved to Yossi Schlessinger’s lab at New York University Medical Center (Pharmacology) in Manhattan, as Marion Abbe Fellow of the Damon Runyon Cancer Research Foundation, prior to moving to Penn in 1996 as Assistant Professor in the Department of Biochemistry and Biophysics (and Johnson Foundation).  Dr. Lemmon’s laboratory ranges from mechanistic, structural, and biochemical to cellular and clinical aspects of signaling by growth factor receptor tyrosine kinases such as EGF receptor family members and ALK.  He is also an expert in phosphoinositide signaling.  His lab has been responsible for much of our current understanding of extracellular regulation of the EGFR.  At Penn, he was promoted to Associate Professor in 2001, to full Professor in 2004, and was appointed Chair of Biochemistry and Biophysics in 2010.  Dr. Lemmon serves on the Editorial Boards of several prestigious journals, including Cell and Molecular Cell, and is Deputy Chair of the Biochemical Journal Editorial Board as well as its Vice-Chair for the Americas.  He also serves on the external advisory board of cancer research programs at MIT, Dana Farber, Kings College London, the University of New Mexico, and the Ontario Institute for Cancer Research, and on the Scientific Advisory Board of Kolltan Inc.  Dr. Lemmon was also Secretary of ASBMB from 2007 to 2013.  His awards include Penn Medicine’s Stanley N. Cohen Research Award in 2009 and the Protein Society’s Dorothy Crowfoot Hodgkin Award in 2012.

« Professor Ruth Plummer
Dr Alan Ashworth »

Cardiology, Diabetes & Nephrology at the Limits Canada
Wednesday, 3 & Thursday, 4 March 2021, Virtual Meeting

Cardiology, Diabetes & Nephrology at the Limits 2021
Monday, 12 & Tuesday, 13 April 2021, Virtual Meeting

The 18th Malvern Diabetic Foot Conference
Wednesday, 12 – Friday, 14 May 2021, Malvern, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 10 & Saturday, 11 September 2021, London, UK

Multiple Sclerosis at the Limits
Monday, 13 & Tuesday, 14 September 2021, London, UK

Hatter Horizon GP Meeting
Monday, 1 November 2021
London, UK

Cell Therapy at the Limits 2021
Monday, 8 & Tuesday, 9 November 2021, London, UK

Hatter Horizon Series
Monday, 22 November 2021, London, UK

Cardiology, Diabetes & Nephrology at the Limits Brazil
Friday, 10 - Saturday, 11 December 2021, São Paulo, Brazil

Policy links

  • Medical Disclaimer
  • Disclosure
  • E-mail Policy
  • Privacy Policy
  • Anti-spam Policy
  • Disclaimer
  • External Links Policy
  • Terms of use
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2021 At the Limits Ltd.
This site uses cookies More info